Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Morphic Holding Inc (MORF)

Morphic Holding Inc (MORF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,025,895
  • Shares Outstanding, K 38,553
  • Annual Sales, $ 19,790 K
  • Annual Income, $ -95,540 K
  • 60-Month Beta 1.26
  • Price/Sales 53.60
  • Price/Cash Flow N/A
  • Price/Book 2.90
Trade MORF with:

Options Overview Details

View History
  • Implied Volatility 36.70% ( +2.82%)
  • Historical Volatility 68.86%
  • IV Percentile 2%
  • IV Rank 5.56%
  • IV High 183.60% on 05/12/22
  • IV Low 28.06% on 08/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 30
  • Open Int (30-Day) 29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.85
  • Number of Estimates 4
  • High Estimate -0.80
  • Low Estimate -0.90
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -49.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.14 +5.77%
on 11/04/22
31.72 -16.17%
on 11/11/22
-2.53 (-8.69%)
since 10/28/22
3-Month
23.03 +15.46%
on 10/24/22
31.72 -16.17%
on 11/11/22
-1.33 (-4.76%)
since 08/29/22
52-Week
19.23 +38.27%
on 06/13/22
52.33 -49.19%
on 01/05/22
-22.09 (-45.38%)
since 11/26/21

Most Recent Stories

More News
Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

MORF : 26.59 (-0.08%)
EVGN : 0.6300 (-6.82%)
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.

VRTX : 316.33 (+0.33%)
CRSP : 52.88 (-0.86%)
MORF : 26.59 (-0.08%)
CDAK : 0.7000 (-4.12%)
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View

BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.

SNY : 45.87 (+0.72%)
BMRN : 97.12 (-1.56%)
MORF : 26.59 (-0.08%)
CDAK : 0.7000 (-4.12%)
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.

BIIB : 291.41 (-0.17%)
RHHBY : 40.6600 (-1.05%)
MORF : 26.59 (-0.08%)
CDAK : 0.7000 (-4.12%)
Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.

PFE : 49.49 (-0.16%)
MRNA : 173.15 (-1.27%)
MORF : 26.59 (-0.08%)
BNTX : 163.61 (+1.31%)
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.

BIIB : 291.41 (-0.17%)
AERI : 15.25 (+0.07%)
IONS : 38.76 (-3.89%)
MORF : 26.59 (-0.08%)
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing

The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.

CPRX : 16.27 (-1.33%)
AERI : 15.25 (+0.07%)
RETA : 39.21 (+2.64%)
MORF : 26.59 (-0.08%)
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

AERI : 15.25 (+0.07%)
AXSM : 70.84 (-5.22%)
RLMD : 4.59 (-6.33%)
MORF : 26.59 (-0.08%)
Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab

Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.

PFE : 49.49 (-0.16%)
MRNA : 173.15 (-1.27%)
MORF : 26.59 (-0.08%)
BNTX : 163.61 (+1.31%)
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency

BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.

NVS : 87.36 (-0.36%)
BMRN : 97.12 (-1.56%)
MORF : 26.59 (-0.08%)
CDAK : 0.7000 (-4.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 28.44
2nd Resistance Point 27.84
1st Resistance Point 27.22
Last Price 26.59
1st Support Level 26.00
2nd Support Level 25.40
3rd Support Level 24.78

See More

52-Week High 52.33
Fibonacci 61.8% 39.69
Fibonacci 50% 35.78
Fibonacci 38.2% 31.88
Last Price 26.59
52-Week Low 19.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar